Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
Phase of Trial: Phase IV
Latest Information Update: 26 Dec 2018
At a glance
- Drugs Apixaban (Primary) ; Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions
- Acronyms COBRRA
- 05 Jan 2018 Planned End Date changed from 1 Jan 2022 to 1 May 2022.
- 05 Jan 2018 Planned primary completion date changed from 1 Sep 2021 to 1 Dec 2021.
- 05 Jan 2018 Status changed from not yet recruiting to recruiting.